This study is in line with the findings of Dominguez et al. [130], which showed that among obese subjects with DM2 diagnosis, TNF-α blocker therapy (etanercept) resulted in a significant reduction in IL-6 and CRP levels but did not result in improvement in β-cell function or insulin sensitivity [130]. The gene discussed is CRP; the disease is myotonic dystrophy type 2.